Effect of angiotensin II receptor blockade on fibrinolysis during acute hyperinsulinemia in patients with essential hypertension

Hypertension

Volumn 27, Issue 6, 1996, Pages 1299-1304

  Seljeflot, Ingebjørg ^a   Moan, Andreas ^a   Kjeldsen, Sverre ^a   Sandvik, Endre ^b   Arnesen, Harald ^a  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^b Stovner Health Care Centre   (Norway)

Author keywords

angiotensin II; catecholamines; fibrinolysis; hyperinsulinism; insulin

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN RECEPTOR; LOSARTAN; RECEPTOR SUBTYPE;

ADULT; AGED; ARTICLE; CATECHOLAMINE BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ESSENTIAL HYPERTENSION; FEMALE; FIBRINOLYSIS; HUMAN; HYPERINSULINEMIA; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0029976555     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.27.6.1299     Document Type: Article

References (38)

1. Paramo JA, Colucci M, Collen D. Plasminogen activator inhibitor in the blood of patients with coronary artery disease. BMJ. 1985; 291:573-574.
2. Hamsten A, Wiman B, deFaire U, Blomback M. Increased plasma levels of a rapid inhibitor of tissue-type plasminogen activator in young survivors of myocardial infarction. N Engl J Med. 1985;313: 1557-1563.
3. Landin K, Tengborn L, Smith U. Elevated fibrinogen and plasminogen activator inhibitor (PAI-1) in hypertension are related to metabolic risk factors for cardiovascular disease. J Intern Med. 1990;227:273-278.
4. Vague P, Juhan-Vague I, Aillaud MF, Badier C, Viard R, Alessi MC, Collen D. Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level, and relative body weight in normal and obese subjects. Metabolism. 1986;35:250-253.
5. Landin K, Stigedal L, Eriksson E, Krotkiewski M, Risberg B, Tengborn L, Smith U. Abdominal obesity is associated with an impaired fibrinolytic activity and elevated plasminogen activator inhibitor-1. Metabolism. 1990;39:1044-1048.
6. Juhan-Vague I, Valadier J, Alessi MC, Aillaud MF, Ansaldi J, Philip-Joet C, Holvoet P, Serradimigni A, Collen D. Deficient t-PA release and elevated PA inhibitor levels in patients with spontaneous or recurrent deep venous thrombosis. Thromb Haemost. 1987;57:67-72.
7. Alessi MC, Juhan-Vague I, Kooistra T, Declerck PJ, Collen D. Insulin stimulates the synthesis of plasminogen activator inhibitor 1 by the human hepatocellular cell line Hep G2. Thromb Haemost. 1988;60:491-494.
8. Kooistra T, Bosnia PJ, Tons HAM, van den Berg AP, Meyer P, Princen HMG. Plasminogen activator inhibitor 1: biosynthesis and mRNA level are increased by insulin in cultured human hepatocytes. Thromb Haemost. 1989;62:723-728.
9. Schneider DJ, North TK, Sobel BE. Stimulation by proinsulin of expression of plasminogen activator inhibitor type-1 in endothelial cells. Diabetes. 1992;41:890-895.
10. Potter van Loon BJ, Kluft C, Radder JK, Blankenstein MA, Meinders AE. The cardiovascular risk factor plasminogen activator inhibitor type 1 is related to insulin resistance. Metabolism. 1993;42:945-949.
11. Grant PJ, Kruithof EKO, Felley CP, Feber JP, Bachmann F. Short-term infusions of insulin, triacylglycerol and glucose do not cause acute increases in plasminogen activator inhibitor-1 concentrations in man. Clin Sci. 1990;79:513-516.
12. Landin K, Tengborn L, Chmielewska J, von Schenck H, Smith U. The acute effect of insulin on tissue plasminogen activator and plasminogen activator inhibitor in man. Thromb Haemost. 1991;65:130-133.
13. Seljeflot I, Eritsland E, Torjesen P, Arnesen H. Insulin and PAI-1 levels during oral glucose tolerance test in patients with coronary heart disease. Scand J Clin Lab Invest. 1994;54:241-246.
14. Bachmann F, Kruithof EKO. Tissue plasminogen activator: chemical and physiological aspects. Semin Thromb Haemost. 1984;10:6-19.
15. Anderson EA, Hoffman RP, Balon TW, Sinkey CA, Mark AL. Hyperinsulinemia produces both sympathetic and neural activation and vasodilation in normal humans. J Clin Invest. 1991;87:2246-2252.
16. Berne C, Fagius J, Niklasson F. Sympathetic response to oral carbohydrate administration: evidence from microelectrode nerve recordings. J Clin Invest. 1989;84:1403-1409.
17. Kleinbaum J, Shamoon H. Selective counter regulatory hormone response after oral glucose in men. J Clin Endocrinol Metab. 1982; 55:787-790.
18. Larsson FT, Wiman B, Olsson G, Angelin B, Hjemdahl P. Influence of metoprolol treatment on sympatho-adrenal activation of fibrinolysis. Thromb Haemoat. 1990;63:482-487.
19. Chandler WL, Veith RC, Fellingham GW, Levy WC, Schwartz RS, Cerqueira MD, Kahn SE, Larson VG, Cain KC, Beard JC, Abrass IB, Stratton JR. Fibrinolytic response during exercise and epinephrine infusion in the same subjects. J Am Coll Cardiol. 1992;19:1412-1420.
20. Jern C, Selin L, Lern S. In vivo release of tissue-type plasminogen activator across the human forearm during mental stress. Thromb Haemost. 1994;72:285-291.
21. van Leeuwen RTJ, Amir K, Andreotti F, Kluft C, Maseri A, Sperti G. Angiotensin II increases plasminogen activator inhibitor type 1 and tissue type plasminogen activator messenger RNA in cultured rat aortic smooth muscle cells. Circulation. 1994;90:362-368.
22. Wright RA, Flapan AD, Alberti KGMM, Ludlam CA, Fox KAA. Effects of captopril therapy on endogenous fibrinolysis in men with recent, uncomplicated myocardial infarction. Am J Coll Cardiol. 1994;24:67-73.
23. Moan A, Risanger T, Eide I, Kjeldsen SE. The effect of angiotensin II receptor blockade on insulin sensitivity and sympathetic nervous system activity in primary hypertension. Blood Pressure. 1994;3: 185-188.
24. Landin K, Tenghorn L, Smith U. Effects of metformin and metoprolol CR on hormones and fibrinolytic variables during a hyperinsulinemic, euglycemic clamp in man. Thromb Haemost. 1994;71:783-787.
25. DeFronzo R, Tobin J, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol. 1979;237:E214-E223.
26. Moan A, Nordby G, Os I, Birkeland K, Kjeldsen SE. Relationship between hemorheological factors and insulin sensitivity in healthy young men. Metabolism. 1994;43:4232-4247.
27. Rånby M, Sundell B, Nilsson T. Blood collection in strong acidic citrate anticoagulant used in a study of dietary influence on basal tPA activity. Thromb Haemost. 1989;62:917-922.
28. Kjeldsen SE, Flaaten B, Eide I, Helgeland A, Leren P. Evidence of increased peripheral catecholamine release in patients with long-standing, untreated essential hypertension. Scand J Clin Invest. 1982;42:217-223.
29. Kluft C, Jie AFH, Rijken DC, Verheijen JH. Daytime fluctuations in blood of tissue-type plasminogen activator (t-PA) and its fast-acting inhibitor (PAI-1). Thromb Haemost. 1988;59:329-332.
30. Ridker PM, Gaboury CL, Colin PR, Seely E, Williams G, Vaughan D. Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II: evidence of potential interaction between the renin-angiotensin system and fibrinolytic function. Circulation. 1993;6:1969-1973.
31. Vaughan DE, Lazos SA, Tong K. Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells: a potential link between the renin-angiotensin system and thrombosis. J Clin Invest. 1995;95:995-1001.
32. Seljeflot I, Arnesen H, Støen R, Lyberg T. Effects of insulin and some vasoconstrictors on the synthesis and release of t-PA and PAI-1 from cultured human umbilical vein endothelial cells. Fibrinolysis. 1995;9:253-257.
33. Kerins DM, Hao Q, Vaughan DE. Angiotensin induction of PAI-1 expression in endothelial cells is mediated by the hexapeptide angiotensin IV. J Clin Invest. 1995;96:2515-2520.
34. Feener EP, Northrup JM, Aiello LP, King GL. Angiotensin II induces plasminogen activator inhibitor-1 and -2 expression in vascular endothelial and smooth muscle cells. J Clin Invest. 1995;95:1353-1362.
35. Rowe JW, Young JB, Minaker KL, Stevens AL, Pallotta J, Landsberg L. Effects of insulin and glucose infusions on sympathetic nervous system activity in normal man. Diabetes. 1981;30:219-225.
36. Mitrakou A, Mokan M, Bolli G, Veneman T, Jenssen T, Cryer P, Gerich J. Evidence against the hypothesis that hyperinsulinemia increases sympathetic nervous system activity in man. Metabolism. 1992;41:198-200.
37. Moan A, Høieggen A, Nordby G, Birkeland K, Eide I, Kjeldsen SE. The glucose clamp procedure activates the sympathetic nervous system even in absence of hyperinsulinemia. J Clin Endocrinol Metab. 1995;80:3151-3154.
38. Feldman RD, Bierbrier GS. Insulin-mediated vasodilation: impairment with increased blood pressure and body mass. Lancet. 1993;342:707-709.